Non-cardiovascular drugs that inhibit hERG-encoded potassium channels and risk of sudden cardiac death

Heart

Volumn 97, Issue 3, 2011, Pages 215-220

  Van Noord, Charlotte ^a,b   Sturkenboom, Miriam C J M ^a   Straus, Sabine M J M ^a,b   Witteman, Jacqueline C M ^a   Stricker, Bruno H Ch ^a,c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b MEDICINES EVALUATION BOARD   (Netherlands)

^c Inspectorate for Health Care   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHLORPHENIRAMINE; CIPROFLOXACIN; CISAPRIDE; CLARITHROMYCIN; CORTICOSTEROID; EBASTINE; ERYTHROMYCIN; FLUOXETINE; GASTROINTESTINAL AGENT; HALOPERIDOL; HORMONE ANTAGONIST; IMIPRAMINE; KETOCONAZOLE; MIZOLASTINE; NEUROLEPTIC AGENT; PHENYTOIN; PIMOZIDE; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG; RISPERIDONE; TAMOXIFEN; THIORIDAZINE; UNINDEXED DRUG;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; COMORBIDITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; GENETIC CODE; HIGH RISK PATIENT; HUMAN; IC 50; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NETHERLANDS; PRIORITY JOURNAL; QT PROLONGATION; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SUDDEN DEATH;

AGED; ANTIPSYCHOTIC AGENTS; COMORBIDITY; DEATH, SUDDEN, CARDIAC; EPIDEMIOLOGIC METHODS; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; POTASSIUM CHANNEL BLOCKERS;

EID: 78651228024     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2009.188367     Document Type: Article

References (25)

1. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart 2003;89:1363-72.
2. Lasser KE, Allen PD, Woolhandler SJ, et al. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002;287:2215-20.
3. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350:1013-22.
4. Al-Khatib SM, LaPointe NM, Kramer JM, et al. What clinicians should know about the QT interval. JAMA 2003;289:2120-7.
5. Roden D. Cellular basis of drug-induced torsades de pointes. Br J Pharmacol 2008;154:1502-7.
6. Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature 2006;440:463-9.
7. Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003;58:32-45. (Pubitemid 36351620)
8. Shah RR. Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing. Drug Saf 2004;27:145-72.
9. Vlug AE, van der Lei J, Mosseveld BM, et al. Postmarketing surveillance based on electronic patient records: the IPCI project. Methods Inf Med 1999;38:339-44.
10. van der Lei J, Duisterhout JS, Westerhof HP, et al. The introduction of computer-based patient records in The Netherlands. Ann Intern Med 1993;119:1036-41.
11. Lamberts H, Wood M, Hofmans-Okkes IM. International primary care classifications: the effect of fifteen years of evolution. Fam Pract 1992;9:330-9.
12. Myerburg RJ, Castellanos A. Language and interpretation of clinical trial outcomes: alternates, surrogates, and composites. Heart Rhythm 2004;1:538-9. (Pubitemid 39467710)
13. Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J 2001;22:1374-450.
14. De Bruin ML, Pettersson M, Meyboom RH, et al. Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur Heart J 2005;26:590-7.
15. WHO. World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999;17:151-83.
16. Woosley RL. Drugs that prolong the QTc interval and/or induce Torsade de Pointes. http:www.azcert.org/medical-pros/drug-lists/drug-lists.cfm. (accessed 10 Feb 2010).
17. Greenland S. Modeling and variable selection in epidemiologic analysis. Am J Public Health 1989;79:340-9.
18. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2010. 2008 http://www.whocc.no/atc-ddd-index/ (accessed 10 Feb 2010).
19. CPMP/ICH/423/02. Note for guidance on the nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. London: CHMP/ICH, 2005.
20. Shah R. Drugs, QTc interval prolongation and final ICH E14 guideline: an important milestone with challenges ahead. Drug Saf 2005;28:1009-28.
21. Straus SM, Sturkenboom MC, Bleumink GS, et al. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J 2005;26:2007-12.
22. Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 2002;62:1649-71.
23. Straus SM, Bleumink GS, Dieleman JP, et al. Antipsychotics and the risk of sudden cardiac death. Arch Intern Med 2004;164:1293-7.
24. Chugh SS, Jui J, Gunson K, et al. Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large U.S. community. J Am Coll Cardiol 2004;44:1268-75.
25. Newton-Cheh C, Eijgelsheim M, Rice KM, et al. Common variants at ten loci influence QT interval duration in the QTGEN Study. Nat Genet 2009;41:399-406.